CCB Portal Please support MJHS Institute
Facebook Twitter YouTube LinkedIn

Interprofessional Webinar Series:
Palliative Care in Parkinson’s Disease and Other Neurodegenerative Diseases

This webinar is presented in collaboration with the
National Hospice and Palliative Care Organization.

Funding Disclosure:  No commercial funding has been accepted for the activity.

Date and Time:  November 5, 2015, 12:30 PM – 1:30 PM ET (Live)

Location:   Online at http://www.mjhspalliativeinstitute.org/e-learning/

Speaker Name and Title:
Mara Lugassy, MD
Palliative Care Physician and Hospice Medical Director
MJHS Hospice and Palliative Care
Assistant Professor, Department of Family and Social Medicine
Albert Einstein College of Medicine

Purpose: The purpose of this webinar is to provide an overview of the role of palliative care in the management of Parkinson’s disease and related neurodegenerative diseases from the time of diagnosis until the end stages.

Objectives:  Participants will be able to:

  1. Describe the clinical presentation, natural history, and prognosis of Parkinson’s disease and other neurodegenerative diseases with Parkinsonian features (multiple system atrophy, progressive supranuclear palsy, and dementia with Lewy bodies).
  2. Recognize the changing needs of both patients and caregivers throughout the course of neurodegenerative disease and the related benefits of palliative care at each point.
  3. Discuss key pharmacologic and nonpharmacologic therapies for both motor and nonmotor symptoms throughout the disease trajectory.

Target Audience: palliative care specialists, pain specialists, primary care providers, nurse practitioners, registered nurses, advanced practice nurses, registered nurses with a specialty in palliative care/hospice, pharmacists, allied health professionals, fellows, residents, and medical students

Criteria for Successful Completion:

  1. Attendance at entire session (mandatory for nurses and social workers)
  2. Submission of completed evaluation form (mandatory to receive CE/CME credit for MDs, nurses, social workers)
  3. Successful completion of a posttest; 80% passing grade (mandatory to receive CE credit for social workers)

Continuing Education Credits:  1.0

Continuing Education Accreditation:

Physicians:  This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Hospice and Palliative Care Organization (NHPCO) and MJHS. NHPCO is accredited by the ACCME to provide continuing medical education for physicians.

NHPCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses:  NHPCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NHPCO designates this live activity for a maximum of 1.0 contact hour. Nurses should claim only the contact hours commensurate with the extent of their participation in the activity. Accredited status by ANCC refers only to continuing nursing education and does not imply endorsement of any commercial product discussed in conjunction with this activity.

Social Workers:  NHPCO is an approved provider of continuing education contact hours by the National Association of Social Workers (Provider #886414158).

This program is Approved by the National Association of Social Workers (Approval #886414158-0) for 1 Pain/Symptom Management continuing education contact hours.

Fees:
Individual:  $25 (includes CME/CE certificate)
Group:  $65 + $5 per CME/CE certificate

Registration fees for webinars are not refundable.

Disclosures

Mara Lugassy, MD, has no financial arrangements or affiliations with any commercial entities whose products, research or services may be discussed in these materials. Any discussion of investigational or unlabeled uses of a product will be identified.

Russell K. Portenoy, MD, Planner, has indicated a relationship with Pfizer Inc. for research grant support.

No other Planning Committee Member has any disclosures.

Planning Committee Members
Barbara Bouton, MA, FT
Colleen Fleming-Damon, PhDc, APRN-BC, ACHPN-BC, C.T.
Steven R. Gardner, MPA, PAHM
Myra Glajchen, DSW
Jennifer Kennedy, RN, MA, BSN, CHC
Russell K. Portenoy, MD
Karen Richards, PhD, EdS
Judith A. Skretny